Date: 2016-05-18
Type of information: Licensing agreement
Compound: GlymaxX®
Company: Thermo Fisher Scientific (USA - MA) ProBioGen (Germany)
Therapeutic area: Allergic diseases - Diagnostic - Technology - Services
Type agreement: licensing
Action mechanism: The GlymaxX® technology, developed by ProBioGen, prevents the synthesis of fucose in cells which are stably modified with a specific enzyme-encoding gene. This enzyme deflects the cellular pathway of fucose biosynthesis with literally no fucose being made anymore. Upon modifying an antibody producer cell with the GlymaxX® enzyme, the antibody’s N-linked carbohydrate part becomes afucosylated, which greatly enhances its Antibody-dependent cell-mediated cytotoxicity activity, i.e. the antibody’s cell-killing potency against cancerous or infected cells. Besides for antibodies GlymaxX® can also be applied for any other recombinant protein.
Disease:
Details: * On May 18, 2016, ProBioGen, a leading specialist for contract development and manufacturing of complex glycoproteins and corresponding technologies, announced that Thermo Fisher Scientific has licensed its GlymaxX® technology for use in development of allergy diagnostics.
Financial terms:
Latest news:
